

Robert S Rosenson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5076189/robert-s-rosenson-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

271
papers

15,692
citations

60
h-index

119
g-index

343
ext. papers

18,768
ext. citations

6.4
avg, IF

6.71
L-index

#	Paper	IF	Citations
271	Trends in High-Intensity Statin Therapy After Myocardial Infarction Among U.S. Adults, 2011-2019.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1870-1872	15.1	0
270	Association of total VLDL particle concentrations with elevated blood viscosity in patients with type 2 diabetes.. <i>Diabetes Research and Clinical Practice</i> , 2021 , 183, 109180	7.4	0
269	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	0
268	A new phenotypic classification system for dyslipidemias based on the standard lipid panel. <i>Lipids in Health and Disease</i> , 2021 , 20, 170	4.4	1
267	Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults. <i>Journal of Headache and Pain</i> , 2021 , 22, 124	8.8	2
266	The Projected Impact of Population-Wide Achievement of LDL Cholesterol . <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	0
265	New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1817-1830	15.1	3
264	Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease. <i>Cardiovascular Diabetology</i> , 2021 , 20, 58	8.7	0
263	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
262	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 677-690	3.9	3
261	Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
260	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <i>Journal of the American Heart Association</i> , 2021 , 10, e019254	6	1
259	Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. <i>Cardiovascular Diabetology</i> , 2021 , 20, 94	8.7	4
258	Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Kidney Medicine</i> , 2021 , 3, 722-731.e1 ⁰	2.8	0
257	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 479-489	3.9	2
256	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 166-173	3.9	13
255	One-year statin persistence and adherence in adults with HIV in the United States. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 181-191	4.9	

254	Existing and emerging therapies for the treatment of familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2021 , 62, 100060	6.3	2
253	Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 1048-1057	3.1	1
252	The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. <i>Lipids in Health and Disease</i> , 2021 , 20, 72	4.4	2
251	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 790-802	59.2	203
250	Association between sepsis survivorship and long-term cardiovascular outcomes in adults: a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2021 , 47, 931-942	14.5	8
249	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , 2021 , 10, e020893	6	0
248	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. <i>JAMA Cardiology</i> , 2021 ,	16.2	12
247	Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	2
246	Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 720-729	4.9	1
245	Triglyceride reduction in secondary atherosclerotic cardiovascular disease prevention: core concepts in contemporary therapeutic targeting. <i>European Heart Journal</i> , 2020 , 41, 1521-1522	9.5	11
244	Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2570-2584	15.1	14
243	Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 131-142	15.1	40
242	Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 260-270	4.9	4
241	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020 , 219, 70-77	4.9	9
240	Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. <i>American Heart Journal</i> , 2020 , 220, 203-212	4.9	4
239	Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era. <i>Journal of the American Heart Association</i> , 2020 , 9, e013744	6	17
238	Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2024-2035	15.1	21
237	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1999-2010	15.1	13

236	Sex Differences in Incident and Recurrent Coronary Events and All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1751-1760	15.1	6
235	Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 636-638	4.9	2
234	Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 1	3.9	
233	Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 251-264	15.1	19
232	Evinacumab in Patients with Refractory Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020 , 383, 2307-2319	59.2	69
231	Reply: Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1503-1504	15.1	
230	Evinacumab for Homozygous Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2020 , 383, 711-720	59.2	166
229	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020 , 17, 491-500	2.2	33
228	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. <i>Journal of Lipid Research</i> , 2019 , 60, 1946-1952	6.3	7
227	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019 , 124, 364-385	15.7	25
226	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019 , 140, 618-620	16.7	46
225	Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 77	8.7	5
224	Dietary Patterns and Incident Heart Failure in U.S. Adults Without Known Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2036-2045	15.1	43
223	Deep learning for cardiovascular medicine: a practical primer. <i>European Heart Journal</i> , 2019 , 40, 2058-2073	3.3	104
222	Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. <i>Diabetologia</i> , 2019 , 62, 948-958	10.3	25
221	Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 189-199	3.9	6
220	PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. <i>PLoS ONE</i> , 2019 , 14, e0210808	3.7	9
219	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2019 , 123, 1202-1207	3	9

218	Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2019 , 4, 865-872	16.2	11
217	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
216	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019 ,	9.5	44
215	Ischemic Event Rates in Very-High-Risk Adults. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2496-2507	15.1	17
214	Statins in the perioperative period. <i>F1000Research</i> , 2019 , 8,	3.6	4
213	Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014. <i>Journal of the American Heart Association</i> , 2019 , 8, e010640	6	17
212	Adherence to Statin Therapy Among US Adults Between 2007 and 2014. <i>Journal of the American Heart Association</i> , 2019 , 8, e010376	6	60
211	Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 233-240	3.9	15
210	Assessment of the 1% of Patients with Consistent . <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 175-180	3.9	13
209	Old Drugs for New Indications in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 223-232	3.9	7
208	Association of lipoprotein-associated phospholipase A and risk of incident atrial fibrillation: Findings from 3 cohorts. <i>American Heart Journal</i> , 2018 , 197, 62-69	4.9	3
207	Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 29-36	3.9	7
206	RE: Praluent (Alirocumab)-Induced Renal Injury. <i>Journal of Pharmacy Practice</i> , 2018 , 31, 138-139	1.3	1
205	Titration to High-Intensity Statin Therapy Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 453-461	3.9	4
204	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 365-372	3.9	16
203	Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 443-451	3.9	6
202	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 314-329	15.1	94
201	Healthcare Utilization and Statin Re-Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	2

200	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. <i>Cardiovascular Research</i> , 2018 , 114, 1073-1081	9.9	29
199	PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS). <i>Circulation</i> , 2018 , 137, 1260-1269	16.7	27
198	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. <i>Nature Reviews Cardiology</i> , 2018 , 15, 9-19	14.8	65
197	Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 601-610	3.9	4
196	Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV-Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. <i>Journal of the American Heart Association</i> , 2018 , 7, e010345	6	18
195	Systematic Review of Methods Used for the Microvascular Assessment of Peripheral Arterial Disease. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 301-310	3.9	9
194	Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). <i>American Journal of Cardiology</i> , 2018 , 122, 768-774	3	13
193	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 96-118	15.1	157
192	Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 294-296	4.9	5
191	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 471-482	15.1	133
190	Dyslipidaemia: Small triumph for fenofibrate therapy in dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2017 , 14, 131-132	14.8	1
189	Lipoprotein-associated phospholipase A and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis. <i>Vascular Medicine</i> , 2017 , 22, 5-12	3.3	11
188	Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2017 , 2, 890-895	16.2	68
187	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 179-186	3.9	52
186	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 187-195	3.9	15
185	Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2696-2706	15.1	53
184	Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1386-1395	15.1	173
183	How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2171-2185	15.1	39

182	Trial designs for statin muscle intolerance. <i>Current Opinion in Lipidology</i> , 2017 , 28, 488-494	4.4	4
181	CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients. <i>Evidence-Based Medicine</i> , 2017 , 22, 184-185		5
180	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1680-1681	15.1	15
179	Primary Care Physician Perspectives on Barriers to Statin Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 303-309	3.9	17
178	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 419-431	3.9	30
177	Reply: Statin Intolerance and Risk for Recurrent Myocardial Infarction, Coronary Heart Disease Events, and All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 685-686	15.1	2
176	Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10, e001632		39
175	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1290-1301	15.1	133
174	Dysfunctional HDL and atherosclerotic cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2016 , 13, 48-60	4.8	384
173	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 305-13	3.9	27
172	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 65-74	3.9	9
171	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. <i>Atherosclerosis</i> , 2016 , 245, 111-7	3.1	43
170	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. <i>Circulation</i> , 2016 , 133, 256-64	16.7	62
169	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
168	Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 323-31	3.9	15
167	The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 777-82	9.4	31
166	Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 525-533	3.9	21
165	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 297-304	3.9	15

164	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1580-90	27.4	307
163	Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 41-50	3.9	10
162	Reply: Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2770	15.1	
161	Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 184-92	15.1	65
160	FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 493-494	8.4	48
159	Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	6
158	Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1864-72	15.1	19
157	Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009. <i>American Heart Journal</i> , 2015 , 170, 249-55	4.9	33
156	Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. <i>Atherosclerosis</i> , 2015 , 241, 176-82	3.1	24
155	Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 270-7	15.1	102
154	Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. <i>Clinical Cardiology</i> , 2014 , 37, 131-9	3.3	22
153	Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event. <i>American Journal of Cardiology</i> , 2014 , 114, 826-31	3	23
152	Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. <i>Circulation Research</i> , 2014 , 114, 1880-9	15.7	32
151	2013 ACC/AHA Guideline: a guideline for the population - without evidence from the population. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 203-4	3.9	4
150	Effect of colesvelam HCl monotherapy on lipid particles in type 2 diabetes mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 229-36	3.9	3
149	Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 1298-306	9.4	55
148	An assessment by the Statin Muscle Safety Task Force: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S58-71	4.9	300
147	Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 86-93	4.9	31

146	Limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 942-3	15.1	2
145	Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease. <i>International Journal of Cardiology</i> , 2014 , 174, 436-9	3.2	5
144	Lipoprotein Measurements in Patients Infected with HIV: Is Cholesterol Content of HDL and LDL Discordant with Particle Number?. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 332-333	4.9	5
143	Declines in coronary heart disease incidence and mortality among middle-aged adults with and without diabetes. <i>Annals of Epidemiology</i> , 2014 , 24, 581-7	6.4	27
142	Association between Ischemic Stroke and Vascular Shear Stress in the Carotid Artery. <i>Journal of Clinical Neurology (Korea)</i> , 2014 , 10, 133-9	1.7	6
141	Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 252-62	27.4	205
140	Beginning to understand high-density lipoproteins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014 , 43, 913-47	5.5	70
139	Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2525-40	15.1	149
138	Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2541-2548	15.1	398
137	When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 332	6	4
136	Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. <i>Diabetes Care</i> , 2013 , 36, 2734-40	14.6	11
135	Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 465-79	3.9	28
134	High-density lipoproteins: a consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 484-525	4.9	215
133	Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. <i>American Journal of Cardiology</i> , 2013 , 112, 664-70	3	52
132	Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. <i>Circulation</i> , 2013 , 128, 1256-67	16.7	151
131	Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 256-62	3.3	7
130	Elevated coronary whole blood viscosity in acute coronary syndrome patients. <i>Clinical Hemorheology and Microcirculation</i> , 2013 , 55, 85-94	2.5	7
129	Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 71-5	3.9	31

128	Clinical trials update Esc congress 2011. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 77-84	3.9	2
127	Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. <i>Journal of Lipid Research</i> , 2012 , 53, 1767-82	6.3	102
126	Phospholipase A2 enzymes and the risk of atherosclerosis. <i>European Heart Journal</i> , 2012 , 33, 2899-909	9.5	97
125	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. <i>American Heart Journal</i> , 2012 , 164, 672-80	4.9	52
124	Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 349-58	3.9	13
123	Importance of blood rheology in the pathophysiology of atherothrombosis. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 339-48	3.9	54
122	Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 534-44	4.9	1
121	Initial combination therapy with metformin plus colessevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 318-24	4.9	11
120	ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2427-63	15.1	278
119	Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. <i>Circulation</i> , 2012 , 125, 1905-19	16.7	614
118	Clinical trials of HDL cholesterol-raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH?. <i>Current Atherosclerosis Reports</i> , 2012 , 14, 190-2	6	4
117	HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. <i>Clinical Chemistry</i> , 2011 , 57, 392-410	5.5	341
116	Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 47-57	3.9	13
115	Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 539-44	3.9	13
114	Recombinant high-density lipoprotein formulations. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 81-7	6	11
113	Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 187-9	6	
112	After FRANCIS: next steps in the clinical evaluation of varespladib methyl. <i>Future Cardiology</i> , 2011 , 7, 11-8	1.3	5
111	Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. <i>European Heart Journal</i> , 2011 , 32, 999-1005	9.5	43

110	Hyperinsulinemia and homeostasis model assessment of insulin resistance as predictors of hypertension: a 5-year follow-up study of Korean sample. <i>American Journal of Hypertension</i> , 2011 , 24, 1041-5	2.3	26
109	Residual microvascular risk in diabetes: unmet needs and future directions. <i>Nature Reviews Endocrinology</i> , 2010 , 6, 19-25	15.2	75
108	Varespladib methyl in cardiovascular disease. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1245-55	5.9	12
107	Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. <i>Diabetes</i> , 2010 , 59, 1153-60	0.9	115
106	Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. <i>Clinical Hemorheology and Microcirculation</i> , 2010 , 44, 193-205	2.5	7
105	Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. <i>Diabetes Care</i> , 2010 , 33, 1337-43	14.6	163
104	Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1079-88	15.1	70
103	Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. <i>American Journal of Medicine</i> , 2010 , 123, 892-8	2.4	30
102	Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. <i>Atherosclerosis</i> , 2010 , 213, 1-7	3.1	37
101	Lp-PLA(2) and risk of atherosclerotic vascular disease. <i>Lancet, The</i> , 2010 , 375, 1498-500	4.0	17
100	Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. <i>Current Opinion in Lipidology</i> , 2010 , 21, 473-80	4.4	30
99	New technologies personalize diagnostics and therapeutics. <i>Current Atherosclerosis Reports</i> , 2010 , 12, 184-6	6	14
98	Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment?. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 151-60	3.9	45
97	Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 439-47	3.9	5
96	Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 421-8	3.9	17
95	Management of hyperlipidemia in older adults. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009 , 14, 49-58	2.6	29
94	ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. <i>Circulation</i> , 2009 , 120, 225-76	16.7	829
93	Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009 , 6, 98-100		1

92	Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. <i>Diabetes Care</i> , 2009 , 32, 1087-91	14.6	51
91	Novel targets that affect high-density lipoprotein metabolism: the next frontier. <i>American Journal of Cardiology</i> , 2009 , 104, 52E-7E	3	13
90	Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 93-101	3.9	56
89	Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. <i>Cardiovascular Drugs and Therapy</i> , 2009 , 23, 289-94	3.9	2
88	A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN. <i>Current Atherosclerosis Reports</i> , 2009 , 11, 161-4	6	1
87	Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. <i>Current Cardiology Reports</i> , 2009 , 11, 445-51	4.2	61
86	Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. <i>Circulation</i> , 2009 , 119, 931-9	16.7	354
85	ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc., and the Pulmonary Hypertension Association. <i>Journal of the American College of Cardiology</i> , 2009 , 52, 1502-17	15.1	1257
84	Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2009 , 3, 17-23	8.9	5
83	Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. <i>Atherosclerosis</i> , 2009 , 204, 342-4	3.1	31
82	Management of non-high-density lipoprotein abnormalities. <i>Atherosclerosis</i> , 2009 , 207, 328-35	3.1	19
81	Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 373, 649-58	40	100
80	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 102, 1K-34K	3	280
79	ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 1502-17	15.1	338
78	Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. <i>International Journal of Cardiology</i> , 2008 , 124, 149-59	3.2	34
77	Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. <i>Atherosclerosis</i> , 2008 , 198, 381-8	3.1	33
76	Role of statin therapy in stroke prevention. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 131-9		
75	Biomarkers, atherosclerosis and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 619-22	2.5	6

74	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 319-35	3.3	192
73	Fenofibrate: treatment of hyperlipidemia and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2008 , 6, 1319-30	2.5	65
72	Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids. <i>Cardiovascular Drugs and Therapy</i> , 2008 , 22, 55-8	3.9	12
71	Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE. <i>Current Atherosclerosis Reports</i> , 2008 , 10, 227-9	6	
70	Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes. <i>Current Cardiovascular Risk Reports</i> , 2008 , 2, 43-46	0.9	1
69	Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. <i>Microcirculation</i> , 2008 , 15, 615-20	2.9	13
68	Cardiovascular disease prevention and care in Latino and Hispanic subjects. <i>Endocrine Practice</i> , 2007 , 13, 77-85	3.2	17
67	Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. <i>Journal of the Cardiometabolic Syndrome</i> , 2007 , 2, 238-43		22
66	SPARCL: statin therapy for stroke patients is not crystal clear. <i>Current Atherosclerosis Reports</i> , 2007 , 9, 213-5	6	1
65	Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. <i>Diabetes Care</i> , 2007 , 30, 1945-51	14.6	96
64	Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007 , 3, 72-3		2
63	Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis. <i>Atherosclerosis</i> , 2007 , 194, 520	3.1	1
62	Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. <i>Atherosclerosis</i> , 2007 , 194, e154-64	3.1	45
61	Statins and sepsis: panacea or Pandora's box? [Authors' Pre-reply]. <i>Lancet Infectious Diseases</i> , 2007 , 7, 80-81	25.5	1
60	Statins and sepsis: multiple modifications at multiple levels. <i>Lancet Infectious Diseases</i> , 2007 , 7, 358-65	25.5	223
59	Field of confusion: future prospects for fibrate therapy in cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2006 , 8, 219-22	6	9
58	Statins: panacea for sepsis?. <i>Lancet Infectious Diseases</i> , 2006 , 6, 242-8	25.5	100
57	Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. <i>Atherosclerosis</i> , 2006 , 185, 327-30	3.1	38

56	Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. <i>Expert Review of Cardiovascular Therapy</i> , 2006 , 4, 871-95	2.5	79
55	Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. <i>American Heart Journal</i> , 2006 , 151, 556-63	4.9	40
54	Critical appraisal of revised cholesterol guidelines for the very high-risk patient. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 173-8	2.5	5
53	Low HDL-C: a secondary target of dyslipidemia therapy. <i>American Journal of Medicine</i> , 2005 , 118, 1067-74	7.4	58
52	Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. <i>Current Opinion in Cardiology</i> , 2005 , 20, 313-7	2.1	13
51	New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. <i>Current Problems in Cardiology</i> , 2005 , 30, 241-79	17.1	20
50	Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. <i>Translational Research</i> , 2005 , 145, 83-7		14
49	Short-term reduction in bone markers with high-dose simvastatin. <i>Osteoporosis International</i> , 2005 , 16, 1272-6	5.3	32
48	Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. <i>Circulation</i> , 2004 , 109, 2613-6	6.7	62
47	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. <i>Circulation</i> , 2004 , 110, e550-3	16.7	86
46	Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers. <i>Intensive Care Medicine</i> , 2004 , 30, 1361-9	14.5	35
45	Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. <i>Atherosclerosis</i> , 2004 , 173, 1-12	3.1	202
44	Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. <i>Clinical Therapeutics</i> , 2004 , 26, 1400-10	3.5	45
43	Current overview of statin-induced myopathy. <i>American Journal of Medicine</i> , 2004 , 116, 408-16	2.4	231
42	Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. <i>Atherosclerosis</i> , 2004 , 177, 77-81	3.1	12
41	Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2004 , 19, 480-7	2.1	14
40	Statin therapy: new therapy for cardiac microvascular dysfunction. <i>European Heart Journal</i> , 2003 , 24, 1993-4	9.5	9
39	Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. <i>American Journal of Cardiology</i> , 2003 , 91, 878-81	3	14

38	Variations of whole blood viscosity using Rheolog-a new scanning capillary viscometer. <i>Clinica Chimica Acta</i> , 2003 , 332, 79-82	6.2	27
37	Antiatherothrombotic effects of nicotinic acid. <i>Atherosclerosis</i> , 2003 , 171, 87-96	3.1	71
36	Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2003 , 1, 495-505	2.5	76
35	Effects of hydration on blood rheology. <i>Clinical Hemorheology and Microcirculation</i> , 2003 , 28, 41-9	2.5	4
34	Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. <i>American Journal of Cardiology</i> , 2002 , 90, 89-94	3	245
33	Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. <i>Clinical Endocrinology</i> , 2002 , 57, 209-14	3.4	33
32	Acute-phase reactants and coronary heart disease. <i>Seminars in Vascular Medicine</i> , 2002 , 2, 417-28		25
31	Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. <i>Current Opinion in Lipidology</i> , 2002 , 13, 625-30	4.4	22
30	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. <i>Current Opinion in Cardiology</i> , 2002 , 17, 325-31	2.1	36
29	Physicians' Interpretation of "class effects": a need for thoughtful re-evaluation. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 19-26	15.1	8
28	Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. <i>Atherosclerosis</i> , 2002 , 160, 41-8	3.1	66
27	Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. <i>Atherosclerosis</i> , 2002 , 161, 433-9	3.1	62
26	Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. <i>American Journal of Transplantation</i> , 2002 , 2, 491-500	8.7	63
25	Elevated blood viscosity in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2001 , 31, 52-7	5.3	11
24	Oral 17beta-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. <i>Atherosclerosis</i> , 2001 , 155, 425-30	3.1	14
23	Comparative study of HMG-CoA reductase inhibitors on fibrinogen. <i>Atherosclerosis</i> , 2001 , 155, 463-6	3.1	42
22	Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. <i>Atherosclerosis</i> , 2001 , 159, 225-30	3.1	8
21	Hypertriglyceridemia and other factors associated with plasma viscosity. <i>American Journal of Medicine</i> , 2001 , 110, 488-92	2.4	37

20	Metastatic tumor infiltration of the pericardium masquerading as pericardial tamponade. <i>American Journal of Medicine</i> , 2001 , 111, 504-5	2.4	2
19	Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. <i>American Journal of Cardiovascular Drugs</i> , 2001 , 1, 411-20	4	50
18	Assessing coronary heart disease risk and managing lipids. <i>Nurse Practitioner</i> , 2001 , 26, 30-2, 34, 37-41; quiz 42-3	0.4	4
17	Basic mechanisms of stroke prevention with lipid-lowering therapy. <i>Current Atherosclerosis Reports</i> , 2000 , 2, 120-5	6	2
16	Biological basis for statin therapy in stroke prevention. <i>Current Opinion in Neurology</i> , 2000 , 13, 57-62	7.1	17
15	Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. <i>Clinical Cardiology</i> , 1999 , 22, 25-8	3.3	42
14	Non-lipid-lowering effects of statins on atherosclerosis. <i>Current Cardiology Reports</i> , 1999 , 1, 225-32	4.2	45
13	Low high density lipoprotein levels are associated with an elevated blood viscosity. <i>Atherosclerosis</i> , 1999 , 146, 161-5	3.1	32
12	Hypertriglyceridemia and coronary heart disease risk. <i>Cardiology in Review</i> , 1999 , 7, 342-8	3.2	13
11	Treatment of severe hypertriglyceridemia lowers plasma viscosity. <i>Atherosclerosis</i> , 1998 , 137, 401-5	3.1	21
10	Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment. <i>Atherosclerosis</i> , 1998 , 140, 167-72	3.1	4
9	Effects of lipids and lipoproteins on thrombosis and rheology. <i>Atherosclerosis</i> , 1998 , 140, 271-80	3.1	145
8	Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. <i>JAMA - Journal of the American Medical Association</i> , 1998 , 279, 1643-50	27.4	663
7	Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 1902-5	9.4	32
6	Safety of combined pravastatin-gemfibrozil therapy. <i>American Journal of Cardiology</i> , 1994 , 74, 499-500	3	31
5	Lovastatin-associated sleep and mood disturbances. <i>American Journal of Medicine</i> , 1993 , 95, 548-9	2.4	21
4	Myocardial injury: the acute phase response and lipoprotein metabolism. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 933-40	15.1	185
3	Gemfibrozil-lovastatin-associated myalgia. <i>American Journal of Cardiology</i> , 1993 , 71, 497	3	7

2	Dissecting aneurysm of the pulmonary trunk in mitral stenosis. <i>American Journal of Cardiology</i> , 1986 , 58, 1140-1	3	18
1	Nemaline cardiomyopathy. <i>American Journal of Cardiology</i> , 1986 , 58, 175-7	3	16